Skip to main content

Table 3 Incidence of potentially relevant 12-month follow-up re-admission

From: A large database study of hospitalization charges and follow-up re-admissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

Re-admissions, n (%)[1]

Full cohort

Single-level only cohort

Group

P value

Group

P value

V-CBA (n = 6588)

rhBMP-2 (n = 9584)

V-CBA (n = 5683)

rhBMP-2 (n = 8505)

Patients with all-cause 12-month follow-up re-admissions [2]

1482 (22.5)

2021 (21.08)

971 (17.1)

1198 (14.1)

Re-admitted patients with potentially relevant procedures/diagnoses [3]

 Subsequent lumbar fusion procedures

623 (9.46)

831 (8.67)

0.0879

208 (3.66)

388 (4.56)

< 0.0001*

 Cardiac complications

47 (0.71)

22 (0.23)

< 0.0001^

25 (0.44)

13 (0.15)

0.0125^

 Deep vein thrombosis

6 (0.09)

3 (0.03)

0.1725

4 (0.07)

3 (0.04)

0.7073

 Hematoma

22 (0.33)

30 (0.31)

0.8878

13 (0.23)

20 (0.23)

0.5990

 Nervous system complications

17 (0.26)

14 (0.15)

0.1422

13 (0.23)

9 (0.11)

0.1990

 Pneumonia

80 (1.21)

73 (0.76)

0.0038^

50 (0.88)

46 (0.54)

0.1432

 Pulmonary embolism

28 (0.43)

37 (0.39)

0.706

19 (0.33)

22 (0.26)

0.8748

 Sepsis

2 (0.03)

5 (0.05)

0.7081

0 (0)

1 (0.01)

1.0000

 Surgical-site infection

15 (0.23)

20 (0.21)

0.8634

8 (0.14)

9 (0.11)

1.0000

 Urinary tract infections

144 (2.19)

171 (1.78)

0.0727

81 (1.42)

93 (1.09)

0.6341

  1. Planned analyses were conducted on the full cohort
  2. Ad hoc analyses were conducted on the single-level only cohort, which only included patients who received treatment at a single level of the spine
  3. *Statistically significant, Fisher’s exact test
  4. ^Statistically significant, Fisher’s exact test. Notably, differences observed in follow-up diagnoses between groups corresponded with significant comparisons in related initial Charlson comorbidities within each cohort (Table 1)
  5. [1]All percentages were based on the total number of patients within each cohort who received V-CBA or rhBMP-2 during the initial procedure
  6. [2]Patients with more than one re-admission were counted only once. Did not include patients who may have received follow-up treatment outside of the Premier Healthcare System
  7. [3]Except subsequent lumbar fusion procedures, repeats of the same diagnosis were counted only once. Did not include patients who may have received follow-up treatment outside of the Premier Healthcare System